Jiangxi Synergy Pharmaceutical Co. Ltd. Class A

Jiangxi Synergy Pharmaceutical Co. Ltd. Class A

SSZSE:300636
6.51
CNY
+0.06
(+0.93%)
0.07EPS
106.79P/E
2.98BMarket Cap
Apr 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.16
0.69
1.25
1.09
1.03
0.86
1.33
1.41
1.92
2.21
1.9
1.81
1.97
1.91
Basic EPS, GAAP
0.14
0.13
0.29
0.25
0.23
0.08
0.16
0.23
0.26
0.31
0.28
0.25
0.17
0.07
Free Cash Flow per Basic Share
- -
0.11
- -
0.14
-0.28
-0.54
-0.69
-0.48
-0.95
-0.35
-0.13
0.35
-0.21
- -
Dividend per Share
0.07
0.03
0.02
0.01
- -
0.03
0.02
0.07
0.07
0.1
0.07
0.07
0.07
0.06
Book Value per Share
0.65
0.97
1.07
1.32
2.04
2.11
2.27
2.65
2.88
3.77
5.26
5.48
5.63
5.68
Tangible Book Value per Share
0.6
0.92
1.05
1.29
1.97
2.03
2.2
2.57
2.81
3.71
5.21
5.43
5.59
5.64
Basic Weighted Avg Shares
122
307
220
230
289
309
309
309
309
326
380
420
420
420
Sales/Revenue/Turnover
142
213
275
250
297
267
413
435
592
720
722
759
829
801
Operating Margin (%)
16.88
23.87
24.58
23.39
24.71
8.39
14.78
20.53
16.77
17.25
16.98
16.19
15.28
9.6
Depreciation Expense
- -
13
15
20
21
24
43
52
52
67
69
115
131
- -
Net Income, GAAP
17
39
63
58
65
25
48
70
81
101
106
107
73
28
Effective Tax Rate (%)
13.45
13.76
13.36
14.1
12.26
6.82
6.53
10.26
8.17
5.16
5.79
7.07
3.29
- -
Profit Margin (%)
11.93
18.44
22.88
23.19
22.06
9.18
11.7
16.09
13.7
13.98
14.68
14.04
8.82
3.48
Working Capital
-26
-16
57
125
370
149
193
407
283
183
495
545
795
655
LT Debt
22
7
8
25
20
- -
114
366
623
329
252
400
187
52
Total Equity
79
118
247
305
637
658
706
817
888
1,320
2,226
2,309
2,365
2,387
Return on Invested Capital (%)
9.29
18.1
22.69
15.29
12.5
3.67
6.08
6.1
5.26
5.56
4.3
3.45
2.41
- -
Return on Capital (%)
15.99
23.16
26.53
18.27
12.97
3.67
6.56
6.78
5.59
5.94
4.68
4.11
2.83
- -
Return on Common Equity (%)
27.16
39.84
34.48
21.04
13.9
3.79
7.08
9.2
9.52
9.12
5.98
4.7
3.13
1.18

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
573
415
129
LT Borrowings
39
38
52
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
420
420
420
Market Capitalization
3,423
2,675
2,977

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,434
1,298
1,051
Cash, Cash Equivalents & STI
274
242
274
Accounts Receivable, Net
126
129
141
Inventories
525
553
544
Total Current Liabilities
788
673
396
Payables & Accruals
- -
- -
- -
ST Debt
573
415
129
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.11%
26.44%
2.45%
Free Cash Flow
261.74%
-114.6%
-159.97%
Net Income, GAAP
9.89%
2.87%
-31.42%
Sales/Revenue/Turnover
13.19%
14.43%
9.19%
Total Cash Common Dividend
208.62%
6.76%
-1.16%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
206
176
188
189
759
2025
187
241
- -
192
829
2026
184
199
225
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.06
0.06
0.03
0.25
2025
0.05
0.09
- -
-0.03
0.17
2026
0.04
0.01
0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.06
0.02
-0.03
0.07
2025
0.01
0.05
- -
0.01
0.07
2026
0.01
0.05
- -
- -
- -

Company Description

CEO
Zheng Wei Pang
Full Time Employees
1,623
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Jiangxi Fengxin Industrial Park Yichun JX China 330700
IPO Date
Mar 31, 2017
Business
Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical intermediates, raw materials, and fine chemicals worldwide, with core products including gabapentin, candesartan cilexetil, celecoxib, aceclofenac, rebamipide, venlafaxine HCl, azilsartan medoxomil, dabigatran etexilate mesylate, amlodipine besylate, mirabegron, empagliflozin, and intermediates for anticoagulants, antihypertensives, anti-inflammatories, antiepileptics, antidepressants, and antiviral drugs; the company serves domestic and international markets in Europe, North America, Japan, South Korea, and other regions. Founded in 2004 and headquartered in Yichun, Jiangxi Province, China, with manufacturing facilities in Fengxin Industrial Park, it operates in the healthcare sector focusing on drug manufacturers for specialty and generic pharmaceuticals, employing approximately 1,362 people. Recent developments include obtaining South Korean regulatory approval and pharmaceutical registration certificates for amlodipine besylate, azilsartan potassium (Amiasartan potassium), and mirabegron in 2025; achieving GMP compliance certification from Jiangxi authorities for empagliflozin in March 2025; securing European marketing authorization for celecoxib; receiving a patent for a triazine ketone compound in April 2025; and reporting first-quarter 2025 revenue of CNY 187 million despite a year-on-year decline.